NASDAQ · Biotechnology

Addex Therapeutics Ltd (ADXN) Stock

$5.89 -0.17% NASDAQ: ADXN Healthcare

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors.

Valuation

MetricValue
Price$5.89
Market Cap$4.24M
P/E Ratio-0.72
P/B Ratio2.08
P/S Ratio67.80
EPS (TTM)$-6.88
52-Week High$12.05
52-Week Low$5.41
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-131.35%
ROA-146.41%
ROCE-76.01%
Gross Margin84.32%
Operating Margin—
Net Margin—
Debt/Equity0.03
Current Ratio0.97

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$1.0M$2.0M$0$0
Operating Profit$-16.0M$-11.0M$-2.0M$-3.0M$-3.0M
Net Profit$-15.0M$-21.0M$-11.0M$7.0M$-7.0M
EPS$-54.00$-55.20$-16.80$8.40$-6.88
Op Margin-531.7%-741.0%-139.1%-681.8%-9390.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$23.0M$8.0M$5.0M$11.0M$6.0M
Total Liabilities$6.0M$3.0M$3.0M$1.0M$2.0M
Cash$20.0M$7.0M$4.0M$3.0M$2.0M
Borrowings$0$0$0$0$0

Latest News

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness GlobeNewswire · Jul 8, 2026 Addex Shareholders Approve All Resolutions at Annual General Meeting GlobeNewswire · Jun 30, 2026 Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... GuruFocus.com · Jun 25, 2026 Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · Jun 25, 2026 Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 GlobeNewswire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-16.0M$-8.0M$-5.0M$-2.0M
Investing Cash Flow$0$0$0$5.0M$-1.0M
Financing Cash Flow$3.0M$2.0M$3.0M$0$0
Net Cash Flow$2.0M$-14.0M$-3.0M$-1.0M$-1.0M
Free Cash Flow$-15.0M$-16.0M$-8.0M$-5.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.10
FCF Yield-38.49%
Quick Ratio0.97
Interest Coverage-145.69
Return 1Y-24.84%
Return 3Y-48.74%
Return 5Y-96.84%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Addex Therapeutics Ltd

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

Addex Therapeutics Ltd is headquartered in CH.

Addex Therapeutics Ltd (ADXN) stock trades at $5.89 with a market capitalization of $4.24M. The stock is valued at a price-to-earnings (P/E) ratio of -0.72, price-to-book of 2.08, price-to-sales of 67.80. Over the past 52 weeks the stock has ranged between $5.41 and $12.05, and currently trades 51.1% below its 52-week high.

On profitability, Addex Therapeutics Ltd generates a return on equity (ROE) of -131.35%, return on capital employed of -76.01%.

Official website: www.addextherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides